Patient involvement at the Medicine Evaluation Board (MEB-CBG)

Annemiek van Rensen, Ph.D

Senior advisor patient participation (PGOsupport, Utrecht, NL)
Member of the Dutch Medicine Evaluation Board (MEB-CBG)

Strategic Business Plan of MEB 2014-2018

- Focus on the entire **life cycle** of a medicinal product
- **Patient** is important stakeholder
- Aim: Exchange knowledge and experience with patients to strengthen the connection to the user's practice
- Transparency on how MEB operates and create support for regulatory decisions



Currently at MEB

- Since 2004 “Overleg CBG patiënt & consument”
  - 4 meetings per year
  - Minutes published on the MEB website
  - Different subjects discussed: product issues, regulatory guidelines, development in medicine regulation, product information, substitution

- Theme-meetings: biosimilars, patient information, PROMs, registries

- Questions from (individual) patient organisations
- Specific (joint) actions in response to events
  - e.g. Thyrax, medicinal products for ADHD, new safety information

Goal: Inform → Inform and listen

Patient involvement in decision making process

- 2013-2014: Pilot on presence of patient representatives during Board meetings
- Since Oct. 2015 – Annemiek van Rensen - Board member with focus on patient- and consumer perspective

Future

MEB wants to strengthen the connection with patient organisations, and involve patients in the decision making process

- Regulatory guidelines
- Scientific Advice, esp. ‘tailored advice’
- Risk Communication Material
- Patient expertise consultation on a (group of) diseases, specific topics (e.g. endpoint selection)

Consultation with patient and consumer organisations

http://english.cbg-meb.nl/human/for-patients-and-consumers